Dan is a Managing Associate who advises clients on a wide range of intellectual property issues, with a focus on contentious life sciences and high-tech work. He has particular experience in biopharmaceutical patent and SPC litigation and has represented clients in some of the most complex technical disputes tried in the English courts.

Dan has advised clients in actions in the High Court and Court of Appeal, and has significant experience acting in multi-jurisdictional disputes, co-ordinating and working with litigation teams in Europe (including in EPO opposition proceedings), North America, Asia and Australia.  

With a keen interest in scientific innovation, Dan is readily able to master highly technical issues and has a strong grasp of the technical and commercial landscape in which his clients operate.

Outside of work Dan loves to travel (particularly if that also involves skiing). He enjoys countryside dog walks and is a passionate rugby fan.

Connect with Dan via LinkedIn or get in touch!

Experience

Dan graduated from the University of Durham in 2011 with a first class BSc in Physics. He then trained and qualified as a Solicitor at a magic circle firm before joining Marks & Clerk Law in November 2016.

• Life sciences sector: experienced in antibodies, vaccines, pharmaceutical formulations, small molecules and second medical use products.

• High-tech sector: advises on FRAND and standard essential patent issues, wireless communication systems, software and web technologies.

• Regulatory: a focus on SPCs (including SPCs for plant protection products), paediatric rewards and marketing authorisations.

• Other matters have involved technologies as varied as fire-rated downlights and zips/closure technologies.

• Advises on matters relating to other IPRs, such as trade marks, designs, copyright and confidential information.

Key cases

• Sun Pharma and Almirall v Janssen Biotech
• Chugai v UCB
• Eli Lilly v Genentech
• Merck Sharp & Dohme v Wyeth
• Regeneron & Teva v Rinat Neuroscience
• Merck Sharp & Dohme v Pfizer